Showing results filtered by:
8 Results
Regular, meaningful engagement with Tribal partners helps NIH ensure American Indians and Alaska Natives are well-represented in research and benefit from its outcomes.
Published: April 6, 2022
Jordan Report 20th Anniversary: Accelerated Development of Vaccines 2002
https://www.niaid.nih.gov/sites/default/files/jordan20_2002.pdf
Last Reviewed: December 31, 2002
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a NIH report published today.
Published: May 22, 2020
The HIV/AIDS: Antiretroviral Drugs module is part of the Pathogens in Augmented Reality (PathogenAR) mobile app. Acquired immunodeficiency syndrome (AIDS) is the most severe phase of infection with human immunodeficiency virus (HIV). There is no effective cure for HIV. However, by taking a combination of antiretroviral drugs, people with HIV can now live long and healthy lives. Antiretroviral
Last Reviewed: February 3, 2021
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine. Additional clinical trials evaluating if L9LS can prevent malaria over six to 12 months against seasonal and
Published: August 4, 2022
Senior Leadership for NIAID's Vaccine Research Center (VRC)
Last Reviewed: February 25, 2025
The 202nd meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Monday, September 12, 2022. Dr. Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:44 a.m. and from 1
Last Reviewed: January 27, 2023
The 206 th meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Tuesday, January 30, 2024. Dr. Jeanne Marrazzo, Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:45 a.m. and from 1
Last Reviewed: May 21, 2024